Form 8-K - Current report:
SEC Accession No. 0000950170-25-068546
Filing Date
2025-05-12
Accepted
2025-05-12 07:06:40
Documents
14
Period of Report
2025-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tngx-20250512.htm   iXBRL 8-K 45974
2 EX-99.1 tngx-ex99_1.htm EX-99.1 182579
3 GRAPHIC img21139354_0.jpg GRAPHIC 83353
4 GRAPHIC img161882633_0.jpg GRAPHIC 785
  Complete submission text file 0000950170-25-068546.txt   502256

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tngx-20250512.xsd EX-101.SCH 48917
17 EXTRACTED XBRL INSTANCE DOCUMENT tngx-20250512_htm.xml XML 4511
Mailing Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215
Business Address 201 BROOKLINE AVENUE SUITE 901 BOSTON MA 02215 (857) 320-4900
Tango Therapeutics, Inc. (Filer) CIK: 0001819133 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39485 | Film No.: 25932557
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)